BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12201361)

  • 1. Normal donor bone marrow is superior to Flt3 ligand-mobilized bone marrow in prolonging heart allograft survival when combined with anti-CD40L (CD154).
    Hackstein H; Wang Z; Morelli AE; Kaneko K; Takayama T; Colvin BL; Bein G; Thomson AW
    Am J Transplant; 2002 Aug; 2(7):609-17. PubMed ID: 12201361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus.
    Morelli AE; Antonysamy MA; Takayama T; Hackstein H; Chen Z; Qian S; Zurowski NB; Thomson AW
    J Immunol; 2000 Jul; 165(1):226-37. PubMed ID: 10861056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
    Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
    Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flt-3 ligand increases microchimerism but can prevent the therapeutic effect of donor bone marrow in transiently immunosuppressed cardiac allograft recipients.
    Antonysamy MA; Steptoe RJ; Khanna A; Rudert WA; Subbotin VM; Thomson AW
    J Immunol; 1998 Apr; 160(8):4106-13. PubMed ID: 9558122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Flt-3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow.
    Khanna A; Antonysamy MA; Subbotin VM; Steptoe RJ; Li W; Rudert WA; Thomson AW
    Transpl Immunol; 1998 Dec; 6(4):225-34. PubMed ID: 10342736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
    Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
    Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.
    Sun W; Wang Q; Zhang L; Liu Y; Zhang M; Wang C; Wang J; Cao X
    Transplantation; 2003 Nov; 76(9):1351-9. PubMed ID: 14627915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow.
    Khanna A; Steptoe RJ; Antonysamy MA; Li W; Thomson AW
    Transplantation; 1998 Feb; 65(4):479-85. PubMed ID: 9500620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis.
    Shimizu K; Schönbeck U; Mach F; Libby P; Mitchell RN
    J Immunol; 2000 Sep; 165(6):3506-18. PubMed ID: 10975872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked inhibition of transplant vascular sclerosis by in vivo-mobilized donor dendritic cells and anti-CD154 mAb.
    Wang Z; Morelli AE; Hackstein H; Kaneko K; Thomson AW
    Transplantation; 2003 Aug; 76(3):562-71. PubMed ID: 12923445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection.
    Metzler B; Gfeller P; Bigaud M; Li J; Wieczorek G; Heusser C; Lake P; Katopodis A
    J Immunol; 2004 Dec; 173(11):7025-36. PubMed ID: 15557200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Buhlman J; Xu J; Flavell RA; Korngold R; Noelle R; Vallera DA
    J Immunol; 1997 Jan; 158(1):29-39. PubMed ID: 8977172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection.
    Hancock WW; Sayegh MH; Zheng XG; Peach R; Linsley PS; Turka LA
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13967-72. PubMed ID: 8943044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunobiology of inductive anti-CD40L therapy in transplantation: allograft acceptance is not dependent upon the deletion of graft-reactive T cells.
    Nathan MJ; Yin D; Eichwald EJ; Bishop DK
    Am J Transplant; 2002 Apr; 2(4):323-32. PubMed ID: 12118853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allograft tolerance induced by intact active bone co-transplantation and anti-CD40L monoclonal antibody therapy.
    Yin D; Ma L; Zeng H; Shen J; Chong AS
    Transplantation; 2002 Aug; 74(3):345-54. PubMed ID: 12177612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance induction through megadose bone marrow transplantation with two-signal blockade.
    Lee EN; Lee J; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Kwon CH; Joh JW; Kim SJ
    J Surg Res; 2006 Jan; 130(1):102-9. PubMed ID: 16183077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions.
    Taylor PA; Lees CJ; Waldmann H; Noelle RJ; Blazar BR
    Blood; 2001 Jul; 98(2):467-74. PubMed ID: 11435318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus.
    Iyengar AR; Bonham CA; Antonysamy MA; Subbotin VM; Khanna A; Murase N; Rao AS; Starzl TE; Thomson AW
    Transplantation; 1997 May; 63(9):1193-9. PubMed ID: 9158008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
    Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.